The vaccine obtained the approval of the Administration National Medicines, Food and Medical Technology (Anmat) to begin the last stage of the clinical trial, and it is expected that by the end of this year it will be available to treat melanoma, the most serious skin cancer.
“The interesting thing about the study is that we were also able to determine that Vaccimel treatment is compatible with so-called ‘immune checkpoint inhibitors’a type of immunotherapy that in recent years has proven to greatly improve the outlook for these patients,” Mordoh said.
Another research team, led by Dr. Gabriel Rabinovich, revolves around Galectin-1 studya protein found in a large number of tumors, including melanoma, lung cancer and breast cancer, and is responsible for evading the attack on the disease from the immune system itself.
This work will allow, in the medium term, to deepen “the incorporation of new tools so that the immune system is activated in diseases in which its action is reduced, such as cancer and others,” Rabinovich explained.
Finally, the third investigation team study the behavior of the hormone progesterone and its implication in some types of breast cancer.
The leader of the research, Dr. Claudia Lana, postulated for the first time in the world that progesterone could cause breast cancer, when it was believed that only the hormone estrogen generated it.
With the clinical trial underway, the team is preparing to evaluate the therapeutic effect of an antiprogestagen on a selected group of breast cancer patients.